Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinson’s disease: a systematic review and meta-analysis
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: To assess the clinical efficacy and safety profile of opicapone (25 and 50 mg once daily) versus placebo. Patients: Levodopa-treated adults with Parkinson’s disease. Material & methods: A systematic review and meta-analysis were conducted. Results: Opicapone provided a greater reduction in the absolute OFF-time, increased the chances of ≥1-h reduction in the OFF-time and ≥1-h increase in the ON-time compared with placebo. Receiving opicapone more often facilitated levodopa dose reduction versus placebo. There were no differences in the occurrence of adverse events (severe and leading to drug discontinuation), but receiving opicapone increased the frequency of dyskinesia. Conclusion: Opicapone demonstrated superior clinical efficacy to placebo, with a comparable general safety profile.
Supplementary Material
File (supplementary tables.docx)
- Download
- 30.87 KB
References
1.
Mu J, Chaudhuri K, Bielza C, de Pedro-Cuesta C, Larrañaga P, Martinez-Martin P. Parkinson’s disease subtypes identified from cluster analysis of motor and non-motor symptoms. Front. Aging Neurosci. 9, 301 (2017).
2.
Baram S, Karlsborg M, Øzhayat EB, Bakke M. Effect of orofacial physiotherapeutic and hygiene interventions on oral health-related quality of life in patients with Parkinson’s disease: a randomised controlled trial. J. Oral Rehabil. 48(9), 1035 (2021).
3.
de Lau L, Breteler M. Epidemiology of Parkinson’s disease. Lancet Neurol. 5(6), 525–535 (2006).
4.
Salamon A, Zádori D, Szpisjak L, Klivényi P, Vécsei L. Opicapone for the treatment of Parkinson’s disease: an update. Expert Opin. Pharmacother. 20(18), 2201–2207 (2019).
5.
Rodrigues FB, Ferreira JJ. Opicapone for the treatment of Parkinson’s disease. Mov. Disord. 18(4), 445–453 (2017).
6.
Marras C, Beck JC, Bower JH et al. Prevalence of Parkinson’s disease across North America. NPJ Parkinsons Dis. 4, 21 (2018).
7.
Chinta S, Andersen J. Dopaminergic neurons. Int. J. Biochem. Cell Biol. 37(5), 942–946 (2005).
8.
Rogers G, Davies D, Pink J, Cooper P. Parkinson’s disease: summary of updated NICE guidance. BMJ 358, j1951 (2017).
9.
Annus Á, Vécsei L. Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy. Drug Des. Devel. Ther. 11, 143–151 (2017).
10.
European Parkinson’s Disease Association (2022). www.epda.eu.com/
11.
Olanow W, Poewe W, Rascol O, Stocchi F. From OFF to ON – treating OFF episodes in Parkinson’s disease. US Neurol. 17(1), 36 (2020).
12.
Poewe WH, Deuschl G, Gordin A, Kultalahti E-R, Leinonen M. Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal Levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol. Scand. 105(4), 245–255 (2002).
13.
Deane K, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst. Rev. 2004(4), CD004554 (2004).
14.
Koller W, Lees A, Doder M, Hely M. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson’s disease patients with motor fluctuations. Mov. Disord. 16(5), 858–866 (2001).
15.
Adler CH, Singer C, O’Brien C et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Arch. Neurol. 55(8), 1089–1095 (1998).
16.
Fabbri M, Ferreira JJ, Lees A et al. Opicapone for the treatment of Parkinson’s disease: a review of a new licensed medicine. Mov. Disord. 33(10), 1528–1539 (2018).
17.
MedlinePlus. Levodopa and carbidopa (2021). https://medlineplus.gov/druginfo/meds/a601068.html
18.
Fernandez HH, Chen JJ. Monoamine oxidase-B inhibition in the treatment of Parkinson’s disease. Pharmacotherapy 27(12 Pt 2), 2007).
19.
Margolesky J, Singer C. Extended-release oral capsule of carbidopa-levodopa in Parkinson disease. Ther.Adv.Neurol.Disord. 11, 1756285617737728 (2018).
20.
Suski V, Stacy M. Dopamine agonists. In: Handbook of Parkinson’s Disease (5th Edition). Pahwa R, Lyons KE (Eds). CRC Press, FL, USA, 414– 429 (2021).
21.
Greenwood J, Pham H, Rey J. Opicapone: a third generation COMT inhibitor. Clin. Park. Relat. Disord. 4, 100083 (2021).
22.
Fox SH, Katzenschlager R, Lim S-Y et al. International Parkinson and Movement Disorder Society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov. Disord. 33(8), 1248–1266 (2018).
23.
Song Z, Zhang J, Xue T et al. Different catechol-O-methyl transferase inhibitors in Parkinson’s disease: a Bayesian network meta-analysis. Front. Neurol. 12, 1657 (2021).
24.
Singh A, Gupta D, Dhaneria S, Sheth PG. Istradefylline versus opicapone for “off” episodes in Parkinson’s disease: a systematic review and meta-analysis. Ann. Neurosci. 28(1-2), 65–73 (2021).
25.
Kwak N, Park J, Kang H-Y, Lee M-J, Suh JK, Lee H. Efficacy and safety of opicapone for motor fluctuations as an adjuvant to levodopa therapy in patients with Parkinson’s disease: a systematic review and meta-analysis. J. Parkinsons Dis. 12(3), 773–783 (2022).
26.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int. J. Surg. 8(5), 336–341 (2010).
27.
EMA. Summary of Product Characteristics. Amsterdam, The Netherlands (2016).
28.
USFDA. Highlights of Prescribing Information MD, USA (2020).
29.
EMA. Committee for medicinal products for human use (CHIMP) assessment Report. Amsterdam, The Netherlands (2011).
30.
Higgins J. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March2011]. Cochrane Collaboration. London, UK (2011).
31.
BIPARK-1. Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson’s Disease Patients with ‘Wearing-off’ Phenomenon – Full Text View – ClinicalTrials.gov (2012). https://clinicaltrials.gov/ct2/show/NCT01568073
32.
Ferreira JJ, Lees A, Rocha J-F, Poewe W, Rascol O, Soares-Da-Silva P. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 15(2), 154–165 (2015).
33.
Lees AJ, Ferreira J, Rascol O et al. Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 74(2), 197–206 (2017).
34.
BIPARK-2. Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson’s Disease Patients – Full Text View – ClinicalTrials.gov (2010). https://clinicaltrials.gov/ct2/show/NCT01227655
35.
Takeda A, Takahashi R, Tsuboi Y et al. Randomized, controlled study of opicapone in Japanese Parkinson’s patients with motor fluctuations. Mov. Disord. 36(2), 415 (2021).
36.
Poewe W, Seppi K, Tanner CM et al. Parkinson disease. Nat. Rev. Dis. Primers 3(1), 1–21 (2017).
37.
Castro Caldas A, Teodoro T, Ferreira JJ. The launch of opicapone for Parkinson’s disease: negatives versus positives. Expert Opin. Drug. Saf. 17(3), 331–337 (2018).
38.
Hauser RA, Gordon MF, Mizuno Y et al. Minimal clinically important difference in Parkinson’s disease as assessed in pivotal trials of pramipexole extended release. Parkinsons Dis. 2014, 467131 (2014).
39.
Palmer CS, Schmier JK, Snyder E, Scott B. Patient preferences and utilities for ‘off-time’ outcomes in the treatment of Parkinson’s disease. Qual. Life Res. 9(7), 819–827 (2000).
40.
Nicholas AP, Borgohain R, Chaná P et al. A randomized study of rotigotine dose response on ‘off’ time in advanced Parkinson’s disease. J. Parkinsons Dis. 4(3), 361–373 (2014).
41.
Chaudhuri KR, Jenner P, Antonini A. Should there be less emphasis on levodopa-induced dyskinesia in Parkinson’s disease? Mov. Disord. 34(6), 816–819 (2019).
42.
Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P. Long-term efficacy of opicapone in fluctuating Parkinson’s disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. Eur. J. Neurol. 26(7), 953–960 (2019).
43.
Takeda A, Takahashi R, Tsuboi Y et al. Long-term safety and efficacy of opicapone in Japanese Parkinson’s patients with motor fluctuations. J. Neural Transm. 128(3), 337–344 (2021).
44.
Ferreira JJ, Lees AJ, Poewe W et al. Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. Neurology 90(21), e1849–e1857 (2018).
45.
Vokurka P, Barron A, Sumaria S et al. Opicapone efficacy and tolerability in Parkinson’s disease patients reporting insufficient benefit/failure of entacapone. Mov. Disord. Clin. Pract. 7(8), 955 (2020).
46.
Reichmann H, Lees A, Rocha JF et al. Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study. Transl. Neurodegener. 9(1), 1–9 (2020).
47.
Nakamagoe K, Tsuji H, Ishii K, Tamaoka A. Remarkable clinical responses of non-fluctuating Parkinson’s disease (PD) after alternating catechol O-methyltransferase inhibitors: case series switching from entacapone 200∼300 mg/day to opicapone 25 mg/day. Neurol. Sci. 42(11), 4813–4814 (2021).
48.
Leta V, Van Wamelen DJ, Sauerbier A et al. Opicapone and levodopa-carbidopa intestinal gel infusion: the way forward towards cost savings for healthcare systems? J. Parkinsons Dis. 10(4), 1535–1539 (2020).
Information & Authors
Information
Published In
Pages: 889 - 904
PubMed: 35758044
Copyright
© 2022 Future Medicine Ltd.
History
Received: 14 February 2022
Accepted: 24 May 2022
Published online: 27 June 2022
Keywords:
Topics
Authors
Funding Information
Jagiellonian University Medical College: N43/DBS/000099
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinson’s disease: a systematic review and meta-analysis. (2022) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2022-0031
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Yuki Yasutaka, Takayasu Mishima, Kentaro Ogata, Akira Yokote, Hidetoshi Kamimura, Yasuhiko Baba, Factors affecting continuation rates of opicapone: A retrospective study at a single center in Japan, Clinical Neurology and Neurosurgery, 10.1016/j.clineuro.2025.108875, 252, (108875), (2025).
- Thomas Müller, Clinical pharmacokinetics of levodopa and relevant add-on therapies for Parkinson’s disease, Expert Opinion on Drug Metabolism & Toxicology, 10.1080/17425255.2024.2428831, 21, 3, (279-288), (2024).
- Wenshuo Wu, Xiaohui Lu, Liping Zhang, Du Hong, Effectiveness and safety of different catechol-o-methyl transferase inhibitors for patients with parkinson’s disease: Systematic review and network meta-analysis, Clinical Neurology and Neurosurgery, 10.1016/j.clineuro.2024.108189, 239, (108189), (2024).
- Matilde Otero-Losada, Paolo Gubellini, Francisco Capani, Santiago Perez-Lloret, Editorial: Neuroprotection and disease modification in Parkinson’s disease: Volume II, Frontiers in Pharmacology, 10.3389/fphar.2022.1121513, 13, (2023).
- Luwen Xie, Xiaoyi Qi, Xuan Wang, Bing He, Yu Wang, Wei Zhang, Zehui Yu, Mingming Deng, Sicheng Liang, Muhan Lü, Adverse event profiles of adjuvant treatment with opicapone in Parkinson’s disease: A systematic review and meta-analysis, Frontiers in Pharmacology, 10.3389/fphar.2022.1042992, 13, (2022).